Halozyme Therapeutics, a San Diego based biopharmaceutical company, announced positive results from two Phase 2 clinical trials of its ultrafast PH20 insulin analog formulations in patients with type 1 and type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1c compared to the insulin analog comparator, Humalog (insulin lispro), with superior reductions in post-prandial glucose excursions in the PH20 insulin analog arms.
The company is planning a complete presentation of the data at a major medical meeting in 2012. Halozyme intends to explore opportunities that could maximize the global availability of its injectable PH20 insulin analog therapy to patients with type 1 and type 2 diabetes. The company also has an ongoing study in patients with type 1 diabetes who use insulin pumps to determine if a single dose of ultra-fast insulin administered at the beginning of each subcutaneous infusion of analog insulin may reduce the variability of insulin absorption over infusion set life. It is hypothesized that more responsive and predictable insulin absorption over infusion set life may enable patients to further reduce glucose excursions on pump therapy.